The landscape of hematological oncology faces a persistent and formidable challenge in the form of acute myelogenous leukemia (AML), a…
Read More
FDA Approves a Wave of Oncology Innovations: New Therapies, Diagnostics, and Imaging Agents Usher in a New Era of Cancer Care
The US Food and Drug Administration (FDA) has recently authorized a series of significant advancements in oncology, encompassing novel therapeutic…
Read More
Johns Hopkins Researchers Uncover Molecular Mechanism Driving Rare Translocation Kidney Cancer Through Liquid Condensate Formation
In a significant advancement for the field of oncology, investigators at the Johns Hopkins Kimmel Cancer Center and the Johns…
Read More
Scientists Replicate Human Bone Marrow Niches in Lab Setting to Revolutionize Blood Cancer Research and Reduce Animal Testing
In a landmark achievement for regenerative medicine and hematology, a multidisciplinary team of researchers from the University of Basel and…
Read More
Cancer Driving Mutations in Brain Immune Cells Linked to Alzheimer’s Disease Progression and Risk
The traditional understanding of Alzheimer’s disease has long centered on the accumulation of amyloid-beta plaques and tau tangles within the…
Read More
Parabilis Medicines Aims for $475 Million Nasdaq IPO to Advance Lead Cancer Asset Zolucatetide
Parabilis Medicines, a promising biotechnology firm, is strategically positioning itself for a significant public market debut, announcing its intention to…
Read More
Regeneron and CytomX extend cancer therapy partnership to $4bn deal
Regeneron Pharmaceuticals and CytomX Therapeutics have significantly expanded their strategic research and licensing collaboration, aiming to pioneer the development of…
Read More
Researchers Create First Fully Human Synthetic Bone Marrow Model to Advance Cancer Research and Reduce Animal Testing
The human bone marrow is often described as the body’s "blood factory," a highly sophisticated and dynamic tissue responsible for…
Read More
Beyond PD-1: The drugs reshaping cancer treatment at ASCO 2026
The biotechnology sector, a critical engine of medical innovation, is experiencing a robust resurgence, marking a significant turnaround from recent…
Read More
ASCO 2026: Navigating the Evolving Landscape of Non-Small Cell Lung Cancer with Promising Data from Eli Lilly and Mixed Reactions for Summit/Akeso
The American Society of Clinical Oncology (ASCO) 2026, held from May 29 to June 2, 2026, served as a critical…
Read MoreYOU MAY HAVE MISSED
